| Literature DB >> 19906288 |
Marc Torrent1, Victòria M Nogués, Ester Boix.
Abstract
BACKGROUND: Much effort goes into identifying new antimicrobial compounds able to evade the increasing resistance of microorganisms to antibiotics. One strategy relies on antimicrobial peptides, either derived from fragments released by proteolytic cleavage of proteins or designed from known antimicrobial protein regions.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19906288 PMCID: PMC2780422 DOI: 10.1186/1471-2105-10-373
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Bactericidal propensity values (PV) for each amino acid.
| Amino acid | PV value |
|---|---|
| R | 0.106 |
| K | 0.111 |
| C | 0.165 |
| W | 0.172 |
| Y | 0.185 |
| I | 0.198 |
| V | 0.200 |
| H | 0.202 |
| N | 0.240 |
| T | 0.242 |
| F | 0.246 |
| L | 0.246 |
| Q | 0.248 |
| G | 0.265 |
| M | 0.265 |
| S | 0.281 |
| A | 0.307 |
| P | 0.327 |
| E | 0.449 |
| D | 0.479 |
Calculations are based on the average half maximal inhibitory concentration, as detailed in the Methods section.
Evaluation of the tested parameter values for the selection of optimal predicting length and gap inclusion.
| Predictive length (Gaps) | Sensitivity | Specificity |
|---|---|---|
| 10 (2) | 92% | 78% |
| 10 (3) | 86% | 82% |
| 10 (4) | 92% | 78% |
| 12 (3) | 88% | 82% |
| 12 (4) | 86% | 84% |
| 14(2) | 86% | 84% |
| 14 (3) | 86% | 84% |
| 14 (4) | 84% | 86% |
Detail of the predicted sequences from the studied antimicrobial proteins.
| Proteins | Identified sequences | Experimental data reported |
|---|---|---|
| hCAP 18 | RKSKEKIGKEFKRIVQRIKD | LLGDFF |
| CAP 11 | LGGRRFRRMVGLRKKFRKTRKRIQKLGRKIGKTGRKVWKAW | G |
| CRAMP | RFKKKISLRAGLLRKGG.... EKLKKIGQKIKNFFQ | |
| BPI | SVHVHISKSKVGWLIQLFHK | |
| Histone H2A | GRGKQGGKVRAKAKTRS//GRVHRLLRKG | |
| Lysozyme | AKSRWYNQTPNRAKRVITTFRT | WDEAAVN |
| Azurocidin | SGGRLSRFPRFVNV | 50% sequence identity with protegrin antimicrobial peptides |
| α-defensin | YGTCIYQGRLWAFCC | R |
| β-defensin | TLQKYYCRVRGGRCAVLSC | GIIN |
| θ-defensin | GLRCICTRGFCRLL | |
| Magainin precursor | IGKFLHSAKKFGK | G |
| Moronecidin | HIFRGIVHVGKTIHRLVT | FFH |
| Pleurocidin | FFKKAAHVGKHVG | GWGS |
| Bacteriocin enterocin | SCNKKGSCPGVKYGKKLGG | KYYGNGV |
| Helveticin J | VVQKGNVGSKYVYGLQLRKGA | No active peptide reported |
| Sarcotoxin IA | WLKKIGKKIERVGQ | W35 is described as a key residue in endotoxin neutralizing activity [ |
| RNase 3 | INNYRWRCKNQNTFLR | TIAMRA |
| RNase 7 | NINKHTKRCK | No active peptide reported |
| SPAG 11K | QLLRHPVKRAPIIRRIP | N -terminus suggested [ |
| Hepcidin | LCRFCCKCCRNKGCGYCCKF | No active peptide reported |
| Ace AMP1 | ICPRVNRIVT | No active peptide reported |
* United States Patent n° 5830860
The first column includes the identified sequences by the prediction approach. The corresponding active peptides previously described in the literature and tested experimentally are included in the adjacent column for comparison. Matching residues between the identified and experimentally active sequences are underlined and highlighted in bold.